advertisement
Bell K 13
Showing records 1 to 13 |
Display all abstracts from Bell K72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol fLorenz K
Trials 2017; 18: 128
72603 The potential impact of recent insights into proteomic changes associated with glaucomaFunke S
Expert review of proteomics 2017; 14: 311-334
73522 Modulation of the immune system for the treatment of glaucomaBell K
Current Neuropharmacology 2017; 0:
72603 The potential impact of recent insights into proteomic changes associated with glaucomaPerumal N
Expert review of proteomics 2017; 14: 311-334
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol fScheller Y
Trials 2017; 18: 128
73522 Modulation of the immune system for the treatment of glaucomaUnd Hohenstein-Blaul NVT
Current Neuropharmacology 2017; 0:
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol fBell K
Trials 2017; 18: 128
73522 Modulation of the immune system for the treatment of glaucomaTeister J
Current Neuropharmacology 2017; 0:
72603 The potential impact of recent insights into proteomic changes associated with glaucomaBell K; Pfeiffer N
Expert review of proteomics 2017; 14: 311-334
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol fGrus F
Trials 2017; 18: 128
73522 Modulation of the immune system for the treatment of glaucomaGrus FH
Current Neuropharmacology 2017; 0:
72603 The potential impact of recent insights into proteomic changes associated with glaucomaGrus FH
Expert review of proteomics 2017; 14: 311-334
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol fPonto KA; Bock F; Cursiefen C; Flach J; Gehring M; Peto T; Silva R; Tal Y; Pfeiffer N
Trials 2017; 18: 128
Issue 18-4
Change Issue
advertisement